ClinicalTrials.gg
Not yet recruitingNCT07946536Updated Nov 18, 2026

A Clinical Trial to Evaluate the Effects of Glow Shakes Premium Collagen Meal Replacement on Nutritional Adequacy, Body Composition, Skin Health, Satiety, and Overall Wellness in Adults Using GLP-1 or Dual-Incretin Medications for Weight Management

An interventional study of Glow Shakes Premium Collagen Meal Replacement Intervention in Weight Management, Obesity and Nutritional Adequacy, sponsored by The Collagen Co. - GLP-1 Users. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by The Collagen Co. - GLP-1 Users · Not applicable, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a single-group, open-label, decentralized clinical trial evaluating the effects of 12 weeks of once-daily consumption of Glow Shakes Premium Collagen Meal Replacement on nutritional adequacy, body composition, skin health, satiety, and overall wellness in 40 adults aged 18-55 years who are currently using a GLP-1 receptor agonist or dual-incretin medication for weight management. All study activities are conducted remotely; participants complete questionnaire assessments and smart scale body composition measurements at home at Baseline, Week 4, Week 8, and Week 12.

Participants replace a typical meal once daily with the study product for 12 consecutive weeks while continuing their existing GLP-1 or dual-incretin medication. The primary objective is to evaluate within-participant change in perceived nutritional adequacy from Baseline to Week 12. Secondary objectives include changes in body fat percentage, muscle mass, perceived skin health, hunger and satiety, hair health, energy and cognitive focus, nail health, gut comfort, metabolism support, physical strength, and product tolerability and satisfaction.

02

Conditions studied

  • Weight Management
  • Obesity
  • Nutritional Adequacy
  • Body Composition
  • Skin Health
  • Hunger and Satiety
  • GLP-1 Receptor Agonist Use

Browse trials for

03

In context

Obesity

11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

This study's planned enrollment of 40 is below the median of 67 across 9,036 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

The Collagen Co. - GLP-1 Users is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-55 years at the time of enrollment.
  • Currently using a GLP-1 receptor agonist or dual-incretin medication for weight management (e.g., semaglutide, tirzepatide, liraglutide) for a minimum of 4 weeks at the time of enrollment, with a stable or documented dose (no dose change within the 4 weeks prior to enrollment).
  • Self-reported interest in supporting weight management, lean muscle maintenance, nutritional adequacy, or beauty-related benefits (e.g., skin, hair, nails) during GLP-1 therapy.
  • Willing and able to use Glow Shakes Premium Collagen Meal Replacement as a once-daily meal replacement (replacing a typical meal) for 12 consecutive weeks and to complete all questionnaire assessments and Withings smart scale body composition measurements at Baseline, Week 4, Week 8, and Week 12.
  • Willing and able to maintain current GLP-1 or dual-incretin medication dose throughout the study duration without planned dose adjustments (except in the event of a medically indicated change).
  • Willing to maintain current diet (except for the study product), exercise routine, and lifestyle habits for the duration of the 12-week study, without introducing any new supplements or products specifically targeting weight loss, appetite, or body composition.
  • In good general health.
  • Resides in the United States.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding at the time of enrollment, or planning to become pregnant during the 12-week study period.
  • Known allergy or intolerance to any ingredient in the Glow Shakes formulation, including milk, whey, or collagen-derived ingredients.
  • Diagnosed with a serious medical condition requiring medical nutritional management, including but not limited to Type 1 diabetes, active cancer, or severe renal or hepatic disease.
  • Currently testing, or plan to in the next 12 weeks, a product for another research study.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Glow Shakes Premium Collagen Meal Replacement Arm

    Dietary Supplement: Glow Shakes Premium Collagen Meal Replacement Intervention

Interventions

  • Dietary supplementGlow Shakes Premium Collagen Meal Replacement Intervention

    Participants will consume one serving once daily - replacing a typical meal such as breakfast or lunch - for 12 consecutive weeks. One serving is prepared by adding the powder to 11.8 fl oz (approximately 350 mL) of water: add water first, then two scoops of powder, and shake for fewer than 10 seconds. Drink immediately after preparation.

06

What researchers measure

Primary outcomes

  1. Change in Perceived Nutritional Adequacy

    Within-participant change in perceived nutritional adequacy assessed via self-report questionnaire

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Change in Body Fat Percentage

    Within-participant change in body fat percentage (%) measured by participant self-administered Withings smart scale

    Time frame: Baseline to Week 12

  2. Change in Muscle Mass

    Within-participant change in muscle mass (kg) measured by participant self-administered Withings smart scale

    Time frame: Baseline to Week 12

  3. Change in Self-Reported Weight Management and Food Cravings

    Within-participant change assessed via the validated Food Cravings Questionnaire-Trait Reduced (FCQ-T-reduced)

    Time frame: Baseline to Week 12

  4. Change in Self-Reported Perceived Skin Smoothness

    Within-participant change in perceived skin smoothness score assessed via self-report questionnaire

    Time frame: Baseline to Week 12

  5. Change in Self-Reported Perceived Skin Elasticity

    Within-participant change in perceived skin elasticity score assessed via self-report questionnaire

    Time frame: Baseline to Week 12

  6. Change in Self-Reported Hunger Intensity

    Within-participant change in perceived hunger intensity assessed via visual analogue scale or equivalent validated hunger/satiety instrument

    Time frame: Baseline to Week 12

  7. Change in Self-Reported Satiety Duration

    Within-participant change in perceived satiety duration assessed via visual analogue scale or equivalent validated hunger/satiety instrument

    Time frame: Baseline to Week 12

  8. Change in Self-Reported Food Craving Scores

    Within-participant change in food craving scores assessed via the Food Cravings Questionnaire-Trait Reduced (FCQ-T-reduced)

    Time frame: Baseline to Week 12

  9. Change in Self-Reported Hair Thickness

    Within-participant change in perceived hair thickness assessed via self-report questionnaire

    Time frame: Baseline to Week 12

  10. Change in Self-Reported Hair Health

    Within-participant change in perceived hair health assessed via self-report questionnaire

    Time frame: Baseline to Week 12

  11. Change in Self-Reported Energy Levels

    Within-participant change in perceived energy levels assessed via self-report questionnaire

    Time frame: Baseline to Week 12

  12. Change in Self-Reported Cognitive Focus

    Within-participant change in perceived cognitive focus assessed via self-report questionnaire

    Time frame: Baseline to Week 12

  13. Change in Self-Reported Nail Thickness

    Within-participant change in perceived nail thickness assessed via self-report questionnaire

    Time frame: Baseline to Week 12

  14. Change in Self-Reported Nail Health

    Within-participant change in perceived nail health assessed via self-report questionnaire

    Time frame: Baseline to Week 12

  15. Change in Gut Comfort and Digestive Health

    Within-participant change in gut comfort and digestive symptom scores assessed via self-report questionnaire

    Time frame: Baseline to Week 12

  16. Change in Self-Reported Metabolism Support

    Within-participant change in perceived metabolism support assessed via self-report questionnaire

    Time frame: Baseline to Week 12

  17. Change in Self-Reported Physical Strength

    Within-participant change in perceived physical strength assessed via self-report questionnaire

    Time frame: Baseline to Week 12

  18. Product Tolerability and Participant Satisfaction

    Participant-reported product satisfaction, acceptability, and tolerability assessed via product satisfaction questionnaire

    Time frame: Week 12

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jan 2027, 2 months later.

Of 164 industry-sponsored interventional studies with no phase under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 27. This study's planned 2 months is below that.

Counting every sponsor, half of 3,858 studies reached it within 22 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Nov 2026
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07946536
Lead sponsor
The Collagen Co. - GLP-1 Users
Collaborators
Citruslabs
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Izaak Woodley
Contact
izaakwoodley@thecollagen.co

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion